Subscribe
23 August 2017Americas

CRISPR Therapeutics teams up with Massachusetts hospital in cancer treatment drive

Gene-editing company CRISPR Therapeutics has partnered with the cancer centre at Massachusetts General Hospital to develop T cell therapies for treating the disease.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
UC, Berkeley files brief in CRISPR Federal Circuit case
31 July 2017   The University of California, Berkeley has filed a brief at the US Court of Appeals for the Federal Circuit in its appeal against a patent decision on the CRISPR/Cas9 technology.
Americas
CRISPR Therapeutics unites with ViaCyte to treat diabetes
19 September 2018   Gene-editing company CRISPR Therapeutics has partnered with regenerative medicine-focused ViaCyte to focus on diabetes treatments.


Editor's picks

Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024

Editor's picks

Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024

More on this story

Americas
CRISPR Therapeutics unites with ViaCyte to treat diabetes
19 September 2018   Gene-editing company CRISPR Therapeutics has partnered with regenerative medicine-focused ViaCyte to focus on diabetes treatments.
Americas
UC, Berkeley files brief in CRISPR Federal Circuit case
31 July 2017   The University of California, Berkeley has filed a brief at the US Court of Appeals for the Federal Circuit in its appeal against a patent decision on the CRISPR/Cas9 technology.

More on this story

Americas
CRISPR Therapeutics unites with ViaCyte to treat diabetes
19 September 2018   Gene-editing company CRISPR Therapeutics has partnered with regenerative medicine-focused ViaCyte to focus on diabetes treatments.
Americas
UC, Berkeley files brief in CRISPR Federal Circuit case
31 July 2017   The University of California, Berkeley has filed a brief at the US Court of Appeals for the Federal Circuit in its appeal against a patent decision on the CRISPR/Cas9 technology.

More features

Moderna wins reprieve in COVID-19 vaccine dispute
Boehringer sues Indian manufacturer over diabetes drug generic
UK judge ends J&J unit’s hopes of reviving Stelara patent
‘It was like starting all over again’: Tobias Wuttke
‘This is a big problem’: The CRISPR controversy and the ‘mess’ at the heart of the EPO’s appeals boards
‘I’m breaking new ground’: Mölnlycke’s first TM attorney charts a new course
Drug approvals up but global innovation declines
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute